MBQ Pharma's Phase 1 Trial Tests a First-in-Class Halt to Metastasis

In oncology, the most feared word is often not the tumor itself, but what comes next: metastasis. The spread of cancer cells to distant organs is responsible for the overwhelming majority of cancer-related deaths, yet therapies designed specifically to block this process remain scarce. A clinical-stage biotech in Puerto Rico, MBQ Pharma, is now running a first-in-human trial for a compound it believes can do exactly that, targeting a pair of cellular drivers long implicated in cancer's deadly migration [MBQ Pharma].

Its lead candidate, MBQ-167, is an oral small molecule designed to simultaneously inhibit two related proteins, Rac and Cdc42. These are GTPases, molecular switches that regulate cell movement and invasion. The company's thesis, born from academic research at the University of Puerto Rico, is that blocking both could halt the spread of established metastases, a mechanism it describes as first-in-class [BIO, June 2022]. The U.S. Food and Drug Administration cleared an Investigational New Drug (IND) application for MBQ-167 in June 2022, allowing the Phase 1 study in patients with advanced breast cancer to proceed [BIO, June 2022].

The Academic Wedge and Grant-Fueled Path

MBQ Pharma's origins are deeply rooted in the local academic ecosystem, a fact that shapes both its strategy and its funding. The intellectual property for MBQ-167 was developed from research conducted by the company's founders at the University of Puerto Rico Medical Sciences Campus and is licensed to the startup [MBQ Pharma website]. Key patents covering the compound have been issued, providing a foundational IP estate. This university spinout model has allowed the company to advance toward the clinic without the typical early venture capital series. Instead, its primary disclosed funding is a $4.4 million grant from the U.S. Department of Defense, awarded in November 2022 [7][10].

CEO Dr. José F. Rodríguez-Orengo, who co-founded the company with colleagues from the university, leads the development effort [PharmaBoardroom]. The ongoing Phase 1 trial (registered under NCT06075810) is evaluating the safety, tolerability, and preliminary efficacy of oral MBQ-167 in participants with advanced breast cancer, a population with limited options once standard therapies fail [11][12]. The company has noted the compound's potential to cross the blood-brain barrier, suggesting a future path into treating central nervous system tumors, but its immediate focus remains squarely on the initial breast cancer indication [BIO, June 2022].

The High-Stakes Clinical Landscape

The bet on Rac/Cdc42 inhibition is a compelling but high-risk biological proposition. The proteins are validated in preclinical models as promoters of cell motility and metastasis, making them a rational target. However, the history of oncology is littered with promising pathways that failed to translate into patient benefit in the clinic. The dual inhibition approach aims for potency but also increases the complexity of managing a compound's safety profile, a critical unknown being explored in the current Phase 1 dose-escalation study.

The company's reliance on non-dilutive grant funding and its low public profile outside of trade publications present a distinct operational model. The absence of disclosed venture investors at this clinical stage is unusual but not unprecedented for asset-centric biotechs emerging from strong academic hubs. It suggests a capital-efficient, milestone-driven approach, though it also raises questions about the runway for the costly later-stage trials that would be required after a successful Phase 1.

• The mechanism gamble. Success hinges on proving that stopping Rac/Cdc42 in humans actually halts metastasis, not just shrinks primary tumors, a clinical endpoint that is notoriously difficult to measure quickly.
• The capital question. The $4.4 million DoD grant is substantial for early research but is likely insufficient to complete Phase 1 and plan for Phase 2. Attracting partnership or investment interest will depend almost entirely on the initial clinical data.
• The geographic strategy. Conducting its first trial in Puerto Rico leverages local clinical infrastructure and expertise, potentially streamlining patient recruitment and trial operations in a defined community.

For patients with advanced breast cancer, the current standard of care often involves a sequential series of treatments,chemotherapies, hormone therapies, CDK4/6 inhibitors, or antibody-drug conjugates,each aimed at controlling the disease for a period until it progresses. Therapies specifically approved to treat or prevent metastasis itself, rather than just killing cancer cells, are exceptionally rare. MBQ-167 represents a direct, if early, attempt to change that equation for this patient population. The next 12 to 18 months will be defining, as the first clinical data readouts will determine whether this academic insight can become a tangible clinical asset.

Sources

1. [MBQ Pharma] Company Website | https://mbqpharma.com
2. [BIO, June 2022] BIO International Convention Exhibitor Profile | https://www.bio.org/events/bio-international-convention/exhibitor-directory/00855011
3. [PharmaBoardroom] José F. Rodríguez-Orengo CEO Interview | https://pharmaboardroom.com/interviews/jose-f-rodriguez-orengo-ceo-mbq-pharma/
4. [MBQ Pharma, November 2023] First-in-Human Dose Announcement | https://mbqpharma.com/mbq-pharma-announces-the-first-in-human-dose-of-mbq-167-for-advanced-breast-cancer-in-a-phase-1-clinical-trial-in-puerto-rico-with-the-dual-targeted-rac-cdc42-inhibitor/
5. [CenterWatch] Clinical Trial Listing NCT06075810 | https://www.centerwatch.com/clinical-trials/listings/NCT06075810/a-study-of-oral-mbq-167-in-participants-with-advanced-breast-cancer
6. [15] Patent References US9,981,980 and US10,392,396
7. [10] $4.4M US DoD Grant Disclosure
8. [11] Clinical Trial Identifier NCT06075810
9. [12] Clinical Trial Reference